Previous 10 | Next 10 |
Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular dystrophy Total company revenue increased from $176.3 million in 2...
100s of companies run trials in Ukraine; some of them will face delays. In the long term, Ukraine may cease to be a favored location for clinical trials. However, neither Russia nor Ukraine are drug manufacturing hubs, and market exposure is minimal. For further details see:...
SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with th...
SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 3:40pm EST. Th...
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13. The on-demand webcast of the se...
FibroGen (NASDAQ:FGEN) and privately-held HiFiBiO Therapeutics announce an extension of their partnership with FibroGen’s exercise of an exclusive license option for HiFiBiO’s anti-CCR8 monoclonal antibody program (HFB1011). Under the terms of the agreement, HiFiBiO will receive...
Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipeline HiFiBiO to receive $35 million option exercise payment, potential milestones and royalties SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 20, 2021 ...
The following slide deck was published by FibroGen, Inc. in conjunction with this event. For further details see: FibroGen (FGEN) Investor Presentation
Image source: The Motley Fool. FibroGen, inc (NASDAQ: FGEN) Q3 2021 Earnings Call Nov 9, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: FibroGen, inc (FGEN) Q3 2021 Earnings Call Transcript
The following slide deck was published by FibroGen, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: FibroGen, Inc. 2021 Q3 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Shares of Beyond, Inc. (NYSE:BYON) fell sharply during Tuesday’s session following weaker-than-expected quarterly results. Beyond posted adj...
FibroGen, Inc. (NASDAQ:FGEN) shares are trading higher Tuesday after the company posted mixed first-quarter financial results. Here's a look a...
U.S. stocks were higher, with the Dow Jones gaining over 80 points on Tuesday. Shares of Tempur Sealy International, Inc. (NYSE:TPX) rose sharply d...